These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20471224)

  • 21. Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects.
    Smith MJ; Cobia DJ; Wang L; Alpert KI; Cronenwett WJ; Goldman MB; Mamah D; Barch DM; Breiter HC; Csernansky JG
    Schizophr Bull; 2014 Mar; 40(2):287-99. PubMed ID: 24342821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.
    Swanson JW; Swartz MS; Elbogen EB; Van Dorn RA
    J Clin Psychiatry; 2004 Dec; 65(12):1666-73. PubMed ID: 15641872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Premorbid adjustment predictors of cognitive dysfunction in schizophrenia.
    Stefanatou P; Karatosidi CS; Tsompanaki E; Kattoulas E; Stefanis NC; Smyrnis N
    Psychiatry Res; 2018 Sep; 267():249-255. PubMed ID: 29940456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
    J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?
    Mallet J; Ramoz N; Le Strat Y; Gorwood P; Dubertret C
    Eur Arch Psychiatry Clin Neurosci; 2017 Oct; 267(7):629-638. PubMed ID: 28190094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
    Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
    Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with the timing and onset of cannabis use and cannabis use disorder: results from the 2007 Australian National Survey of Mental Health and Well-Being.
    Butterworth P; Slade T; Degenhardt L
    Drug Alcohol Rev; 2014 Sep; 33(5):555-64. PubMed ID: 25186194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
    Tollefson GD; Andersen SW; Tran PV
    Biol Psychiatry; 1999 Aug; 46(3):365-73. PubMed ID: 10435202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
    Perkins D; Lieberman J; Gu H; Tohen M; McEvoy J; Green A; Zipursky R; Strakowski S; Sharma T; Kahn R; Gur R; Tollefson G;
    Br J Psychiatry; 2004 Jul; 185():18-24. PubMed ID: 15231551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
    Lecardeur L; Meunier-Cussac S; Dollfus S
    Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia.
    Morales-Muñoz I; Jurado-Barba R; Caballero M; Rodríguez-Jiménez R; Jiménez-Arriero MÁ; Fernández-Guinea S; Rubio G
    J Neuropsychiatry Clin Neurosci; 2015; 27(1):48-53. PubMed ID: 25716487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of cannabis in cognitive functioning of patients with schizophrenia.
    Schnell T; Koethe D; Daumann J; Gouzoulis-Mayfrank E
    Psychopharmacology (Berl); 2009 Jul; 205(1):45-52. PubMed ID: 19326102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study.
    Machielsen MWJ; Veltman DJ; van den Brink W; de Haan L
    Schizophr Res; 2018 Apr; 194():32-38. PubMed ID: 28351544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.
    Akerele E; Levin FR
    Am J Addict; 2007; 16(4):260-8. PubMed ID: 17661193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder.
    Braga RJ; Burdick KE; Derosse P; Malhotra AK
    Psychiatry Res; 2012 Dec; 200(2-3):242-5. PubMed ID: 22818174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premorbid adjustment in first episode schizophrenia and schizoaffective disorders: a comparison of social and academic domains.
    Norman RM; Malla AK; Manchanda R; Townsend L
    Acta Psychiatr Scand; 2005 Jul; 112(1):30-9. PubMed ID: 15952943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
    Makkos Z; Fejes L; Inczédy-Farkas G; Kassai-Farkas A; Faludi G; Lazáry J
    Neuropsychopharmacol Hung; 2011 Sep; 13(3):127-38. PubMed ID: 21876221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Familial and socioeconomic contributions to premorbid functioning in psychosis: Impact on age at onset and treatment response.
    Hatzimanolis A; Stefanatou P; Kattoulas E; Ralli I; Dimitrakopoulos S; Foteli S; Kosteletos I; Mantonakis L; Selakovic M; Soldatos RF; Vlachos I; Xenaki LA; Smyrnis N; Stefanis NC
    Eur Psychiatry; 2020 Apr; 63(1):e44. PubMed ID: 32345391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.